Al-Jazeera
BRAZIL recently approved CoronaVac, the vaccine made by Beijing-based company Sinovac, thereby enabling Latin Americas largest nation to begin their immunization program. CoronaVac has demonstrated 100 percent protection against severe Covid-19 and hospitalization in the recently-concluded clinical trial involving 12,476 healthcare workers in Brazil. This trial is currently the only publicly disclosed phase 3 clinical trial (involving Covid-19 vaccines), where participants were all healthcare workers working in hospitals. Accordingly, it provides an actual indication of the capability of this vaccine to protect the critical healthcare workforce.